MRX 34

Drug Profile

MRX 34

Alternative Names: miR-34 - Synlogic; miR-34 mimic - Synlogic; MRX-01; MRX34

Latest Information Update: 26 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Asuragen
  • Developer Cancer Prevention & Research Institute of Texas; Mirna Therapeutics
  • Class Antineoplastics; MicroRNAs
  • Mechanism of Action Tumour suppressor gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Haematological malignancies; Liver cancer; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 28 Aug 2017 Synlogic has merged with Mirna Therapeutics forming Synlogic
  • 09 May 2017 Mirna Therapeutics withdraws a phase II trial prior to enrolment for Melanoma and Renal cell carcinoma (IV)
  • 09 May 2017 Mirna Therapeutics closes IND application filed with the US FDA for Liver cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top